AstraZeneca, Pfizer, GlaxoSmithKline: Emerging Markets Earnings Roundup (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights. Part one covered analysis of Eli Lilly, J&J and Novartis.
You may also be interested in...
Pfizer Weighs Options For Future Of Established Products Business Unit As Revenues Show Strong Trends: Emerging Markets Earnings Roundup (Part 3)
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Perhaps the most interesting Q call of all was Pfizer Inc., which discussed in more detail whether it plans to spin out its emerging markets unit.
Pfizer Weighs Options For Future Of Established Products Business Unit As Revenues Show Strong Trends: Emerging Markets Earnings Roundup (Part 3)
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Perhaps the most interesting Q call of all was Pfizer Inc., which discussed in more detail whether it plans to spin out its emerging markets unit.
Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China